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Abstract Research on patient-reported outcomes indicates
that constipation is a common adverse effect of chemother-
apy, and the use of 5-hydroxytryptamine (serotonin; 5HT3)
receptor antagonists aggravates this condition. As cancer
patients take multiple drugs as a part of their clinical man-
agement, a non-pharmacological self-management (SM) of
constipation would be recommended. We aimed to evaluate
the effectiveness of a SM program on antiemetic-induced
constipation in cancer patients. Thirty patients with breast
cancer, receiving 5HT3 receptor antagonists to prevent emesis
during chemotherapy were randomly assigned to the inter-
vention or control group. The SM program consisted of
abdominal massage, abdominal muscle stretching, and edu-
cation on proper defecation position. The intervention group
started the program before the first chemotherapy cycle,
whereas patients in the wait-list control group received the
program on the day before their second chemotherapy cycle.
The primary outcome was constipation severity, assessed by
the constipation assessment scale (CAS, sum of eight com-
ponents). The secondary outcome included each CAS com-
ponent (0–2 points) and mood states. A self-reported
assessment of satisfaction with the program was performed.
The program produced a statistically and clinically significant
alleviation of constipation severity (mean difference in CAS,
-3.00; P = 0.02), decrease in the likelihood of a small vol-
ume of stool (P = 0.03), and decrease in depression and
dejection (P = 0.02). With regards to program satisfaction,
43.6 and 26.4 % patients rated the program as excellent and
good, respectively. Our SM program is effective for miti-
gating the symptoms of antiemetic-induced constipation
during chemotherapy.
Keywords Constipation  Antiemetic  Breast cancer 
Supportive care  Exercise  Self-management
Introduction
Research on patient-reported outcomes in cancer treatment
indicates that constipation is one of the most common and
distressing side effects of cancer therapy [1, 2]. The use of
5-hydroxytryptamine (serotonin; 5HT3) receptor antagonist,
which is commonly included as part of the pharmacologic
treatment of cancer to alleviate emetogenesis, often
increases the severity of constipation [3–5]. Although con-
stipation is a significant health issue related to chemother-
apy, the incidences of constipation (defined by the Common
Terminology Criteria for Adverse Events version 4.0 or
CTCAEv4.0 for short) in clinical trials are frequently under-
reported as physicians are often not made aware of this
symptom [4]. The incidence of 5HT3 receptor antagonist-
induced constipation increases in conjunction with the
emetogenic risk of the chemotherapy medication used. For
instance, the incidence rate of constipation with the use of
5-fluorouracil-epidoxorubicin-cyclophosphamide, a regi-
men with a high emetic risk, is reported to be as high as
84 %, compared to a constipation incidence of 50 % with
use of low emetic risk drugs, such as docetaxel and pacli-
taxel [4, 5]. The combination of a 5HT3 receptor antagonist
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and a corticosteroid is recommended as an antiemetic pro-
phylaxis in patients with a high or moderate-to-high emetic
risk, whereas 5HT3 is not routinely prescribed to patients
with a low emetic risk [6].
Physical exercise facilitates bowel movement and is
recommended for patients with chronic constipation or
irritable bowel syndrome [7–12]. Abdominal massage has
also been emphasized as a non-pharmacological interven-
tion to improve chronic constipation [13–15]. Additionally,
a proper defecation position can ensure the smooth passage
of stool during defecation [16–18]. As cancer patients often
take multiple medications to alleviate the side effects of
chemotherapy, a non-pharmacological intervention to alle-
viate constipation would be favorable, while avoiding the
adverse side effects commonly associated with laxatives,
including bloating, increased gas, and abdominal fullness.
Self-care management and lifestyle education during
cancer treatment are important to minimize antiemetic-in-
duced constipation [3, 19]. Therefore, the aim of our
clinical trial was to evaluate the effectiveness of a self-
management (SM) program in mitigating the symptoms of
antiemetic-induced constipation in cancer patients.
Patients and methods
Study design and patients
A randomized, waiting-list controlled, parallel group,
open-label pilot trial was conducted. This trial was
approved by the ethics committee of Kyoto University
Graduate School and Faculty of Medicine, and was regis-
tered with the University Hospital Medical Information
Network in February 2013 (UMIN000009676).
Breast cancer patients were recruited from Kyoto
University Hospital, Kyoto, Japan, between February 2013
and March 2014, according to the following inclusion
criteria: suitable candidate for chemotherapy; planned
prescription of 5HT3 receptor antagonist, including
ondansetron, granisetron, tropisetron, or palonosetron; an
Eastern Cooperative Oncology Group Performance Status
of 0 or 1; ability to defecate and normal digestive and
abdominal functions before study enrollment; and provi-
sion of signed informed consent. Prospective patients were
further screened on the following exclusion criteria: diffi-
culty communicating due to a mental disorder, cognitive
impairment, or physical disability; constipation severity
score higher than a CTCAEv4.0 grade 2 before enrollment;
pregnancy; restrictions or contraindications to exercise; not
suitable for study inclusion based on the primary physi-
cian’s judgment; and indication of intent to continue taking
non-prescribed supplements. Note that the final exclusion
criterion was added to the protocol in July 2013 and this
change did not affect the measured outcome of the previ-
ously enrolled patients as the use of non-prescribed sup-
plements has consistently been strongly discouraged during
chemotherapy because of possible drug–drug interactions.
Independent research staff performed block random-
ization of recruited patients into the intervention or the
control group, using a block size of 4 and a computer-
generated random-numbers table. Patients were random-
ized (1:1) into an intervention or waiting-list control group.
An occupational therapist verified the allocation by phone
and consulted with the patients in the intervention group
regarding the SM program.
Patient-reported outcomes were assessed before
chemotherapy (baseline), after the first cycle of chemotherapy
(C1) in the hospital and after the second cycle of
chemotherapy (C2) through out-patient care. Activity moni-
tors were provided only during C1.
Standard care (provided to all patients)
On the day before chemotherapy, general self-care infor-
mation was provided for constipation regarding the use of
medication (magnesium oxide, sennoside, and sodium
carbonate suppository), and the benefits of food and drink
intake, circadian rhythms, a relaxing environment, a bidet,
and moderate exercise.
Intervention
The intervention group was educated on the SM program,
which included (a) abdominal massage, (b) abdominal
exercise, and (c) information on the proper defecation
position, on the day before C1 (Fig. S1). This simple SM
program was taught using an illustrated guide that patients
could easily learn in approximately 10 min. The waiting-
list control group was educated on the program on the first
day of C2, before chemotherapy was administered.
Abdominal massage
Patients were informed that abdominal massage could
promote bowel motility throughout the colon (Fig. S1a)
[15]. This massage was performed by applying a constant
moderate pressure to the abdomen using two or three fin-
gers. Small, clockwise circular movements were performed
over the colon. Each pass of the massage required
approximately 1 min and patients were instructed to repeat
the massage 10 times per day.
Abdominal exercise
Three abdominal exercises (Fig. S1b, i–iii) and abdominal
breathing were taught to patients. Based on a number of
100 Breast Cancer Res Treat (2016) 155:99–107
123
yoga poses and a cyclic abdominal stretching protocol for
irritable bowel syndrome [12], these exercises were
designed for breast cancer patients to stimulate and
increase the movement of bowel content, while avoiding
excessive compression or extension of the skin around the
breasts. The three exercises are described below.
1. Wind-relieving Pose: Patients wrapped their hands
around one knee and pulled it gently toward their chest
and drew their head to their knees. They held the
position for 15–30 s while taking slow, deep, calm
breaths. The position, with end-position static hold,
was repeated with the opposite knee.
2. Knees-to-chest Pose: Patients lay down on their back,
drawing their knees toward their chest and interlacing
their hands on top of their knees.
3. Reclined Spinal Twist: Patients lay down on their back
with their knee flexed to approximately 90 and their
feet resting on a bed. Then, the trunk and pelvis were
rotated and held at 80 % of the patient’s maximal
rotation angle for 1 min. The twisting position was
then repeated using the other knee.
Following these exercises, patients performed abdomi-
nal breathing by lying on their back, placing their hands on
their abdomen, and breathing deeply. These exercises
required 5–6 min to complete, and patients were instructed
to repeat them 10 times per day. Abdominal massage and
abdominal exercise were logged by using an Actiwatch
(Cambridge Neurotechnology, Ltd.) and by self-reporting
by patients.
Proper defecation position
Defecating in a semi-squatting position [14, 15] was
introduced to patients through an explanation of anorectal
anatomy and abdominal and thoracic pressures during
defecation (Fig. S1c). To maintain the proper position
during excretion, a small step and cushion were provided.
Outcome measures
The primary endpoint was the constipation status, assessed
using the constipation assessment scale (CAS). Secondary
endpoints were each component of the CAS, mood states
measured by the profile of mood states (POMS), and
health-related quality of life (HRQOL). The frequency of
laxative use and defecation, food and water intake, and
rest-activity patterns, as well as adherence and satisfaction
with the program were also measured. Outcomes were
assessed before chemotherapy (baseline), at C1, and at C2.
The CAS is an eight-item, self-reported measure
designed to assess the presence and severity of constipation
[20–22]. The eight items evaluated by the CAS are
abdominal distention or bloating; change in amount of gas
passed rectally; less frequent bowel movements; rectal
fullness or pressure; rectal pain with bowel movements;
small volume of stool; inability to pass stool; and oozing
liquid stool. The Japanese version of the CAS, which has
been modified and validated to assess constipation in
Japanese populations [21], was used. A low score on the
CAS is indicative of less severe constipation.
The POMS is a self-administered test that identifies and
assesses transient, fluctuating affective states in individuals
[23–25]. The test assesses the following six components of
mood, with higher scores indicative of greater distur-
bances: tension-anxiety, anger-hostility, fatigue-inertia,
depression-dejection, vigor-activity, and confusion-bewil-
derment. In this study, the short version of the POMS was
used.
The Short Form 36 Health Survey (SF36) assesses the
following eight areas of general health: disease-related
limitations in physical activities; limitations in social
functioning as a result of physical and/or emotional prob-
lems; limitations in participating in a usual role or function
(work or other daily activities) as a result of emotional
problems; limitations in participating in a usual role or
functioning as a result of physical health problems; bodily
pain; general mental health (feelings about well-being or
depression); vitality (energy and fatigue); and general
health perceptions [26–28]. Scores ranging from 0 to 100
were calculated for each of these different health aspects,
with a low score indicative of a poor health status. In this
study, the standard version of the SF36 was used for
baseline assessment, and the abbreviated version was used
at the follow-up time points.
The wrist actigraph, Actiwatch, which is designed to
provide accurate and objective sleep and wake activity,
was used to determine abnormal rest-activity patterns [29,
30]. By clicking on the markers, a complete list of the
times when the marker button on the side of the Acti-
watch has been pressed is provided. Patients wore the
Actiwatch continuously on their non-dominant forearm,
and they pushed the marker when they slept and woke up to
log their subjective rest-activity patterns. Patients in the
intervention group were also required to push the marker
when they started and finished the SM program to assess
adherence objectively.
Laxative use, food and water intake, and frequency of
defecation, nausea, or vomiting were also self-reported by
patients. The daily use of laxatives (magnesium oxide,
sennoside, or sodium carbonate suppository); amount of
food and water intake; and frequency of defecation, nausea,
or vomiting (CTCAEv 4.0) were reported throughout the
trial.
The self-report satisfaction questionnaire included (1)
ease of use; (2) perception of whether it was effective; (3)
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desire to continue; and (4) timing of the intervention.
Patients were asked to respond to each question with a
grade of ‘‘bad,’’ ‘‘poor,’’ ‘‘fair,’’ ‘‘good,’’ or ‘‘excellent.’’ A
free writing space was also provided to obtain subjective
feedback. This questionnaire was added to the protocol in
July 2013.
Sample size and data analysis
All the data were double checked by a third-party benefi-
ciary. The data plausibility and the analysis were super-
vised by a statistician. Statistical analyses were performed
using the full analysis set (Fig. 1). Age, weight, and body
mass index (BMI) are presented as mean and standard
deviation (SD). The regimen of chemotherapy and dose of
palonosetron are presented according to the number of
patients. The total CAS score—a primary endpoint after
C1—was adjusted by the baseline score (C1-baseline), is
presented as mean (SD), and was compared between the
two groups using Student’s t test. Each component of the
CAS was adjusted by the baseline score (C1-baseline), is
presented as mean (SD), and was analyzed using the Wil-
coxon rank-sum test. To perform a graphical evaluation of
each CAS component, radar plots were created to report
the dimension scores. Mood states and the HRQOL are
presented as mean (SD), and were analyzed using the
Wilcoxon rank-sum test.
The number of patients who showed abnormal rest-ac-
tivity patterns, as assessed by actigraphy, and nausea and
vomiting, as assessed by the CTCAEv4.0 grade 2, was also
determined. The use of laxatives, food intake, and fre-
quency of defecation are presented as mean (SD). The
patients’ impression and satisfaction with the program are
presented using percentage bar charts, based on the number
of patients for each answer.
The sample size was not determined based on a formal
power calculation but rather on the number of patients that
could realistically be recruited from the target patient
Fig. 1 CONSORT diagram
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population within the study period. With 30 patients
enrolled in the study, our sample size was similar to a
previous trial [13].
All P values were two-sided, and P values\0.05 were
considered statistically significant. All statistical analyses
were performed using SAS, version 9.3 (SAS Institute
Inc.) and R (R Foundation for Statistical Computing).
Results
Patient recruitment and characteristics
Thirty patients who met the eligibility criteria were ran-
domized (1:1) into an intervention or waiting-list control
group. Table 1 summarizes patients’ characteristics. Age,
weight, BMI, and chemotherapy regimen were comparable
between the intervention and control groups.
Adherence to the intervention program
All patients received the same instructions regarding the
goals of the program and the manner in which it can be
performed. Patients in the intervention group performed
abdominal massage, on average, 3.82 times per day and
abdominal muscle stretching 3.57 times per day. No
patients in either group reported exercise-induced stomach
discomfort, and all preferred continuing the SM program
during chemotherapy.
Primary endpoint
Figure 2 shows the change in antiemetic-induced consti-
pation during chemotherapy as a proportional change of the
total CAS score. The change in the CAS score was adjusted
by the baseline score and plotted using a boxplot. The
mean change in the CAS was significantly and clinically
lower in the intervention group, compared to the control,
with a mean between-group difference of approximately
40 % [mean difference = -3.00; 95 % confidence interval
(CI), -5.46 to -0.54; P = 0.019].
All the patients in the waiting-list control group were
educated regarding the program after the C1 (no interven-
tion) assessment and just prior to C2. In Fig. 2, the box on the
right shows the score after C2, adjusted by the baseline score,
for the waiting-list control group. Patients after the inter-
vention program (C2) reported a lower severity of consti-
pation as compared to the period when they had were yet
instructed for the intervention program, the boxplot in the
middle (C1). Changes for each patient in the intervention and
control groups (baseline, C1, and C2) are shown in Fig. 3.
Secondary endpoints
Figure 4 shows the individual scores of the eight compo-
nents of the CAS on a radar plot. There was a significant
between-group difference in the component of small vol-
ume of stool (P = 0.032). The score of each CAS com-




Intervention (n = 15) Control (n = 15) Overall (n = 30)
Demographic profile, mean (SD)
Age (years) 55.3 (12.6) 54.9 (9.7) 55.1 (11.0)
Medical profile, mean (SD)
Weight (kg) 54.8 (9.6) 56.7 (10.0) 55.8 (9.7)
BMI (kg/m2) 22.4 (4.3) 23.0 (4.2) 22.7 (4.2)
Chemotherapy, n (%)
High emetic risk 8 (53.3) 10 (66.7) 18 (60.0)
Moderate emetic risk 7 (46.7) 5 (33.3) 12 (40.0)
Taxotere or docetaxel use 3 (20.0) 4 (26.7) 7 (23.3)
Palonosetoron use, n (%)
0.75 mg 13 (86.7) 14 (93.3) 27 (90.0)
0.30 mg 2 (13.3) 1 (6.7) 3 (10.0)
SD standard deviation
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As evident in Table S2, the depression-dejection score
of the POMS was significantly lower for the intervention
group, compared to the control group (P = 0.021). No
between-group differences were identified for tension-
anxiety, anger-hostility, vigor, fatigue, or confusion.
The intervention had no significant effect on HRQOL
(Table S2). No notable differences were observed in the
use of laxatives, food intake, and frequency of defecation,
nausea, or vomiting between the groups (Table S3). No
patients showed abnormal rest-activity patterns, such as
reverse cycling or sleeplessness.
In the satisfaction questionnaire, nearly half of the
patients (43.6 %) rated the program as excellent, whereas
26.4 % rated it as good (Fig. 5).
Discussion
Our study findings support our priori hypothesis that a SM
program could mitigate the symptoms of antiemetic-in-
duced constipation. The severity of constipation was
approximately 40 % lower in the intervention group,
compared to the control group, with a mean CAS score of
\5 points in the intervention group, which is indicative of
mild constipation not requiring medical intervention. With
regard to the mood states, depression-dejection was less
frequently reported by the intervention group than by the
control group. Over half of the patients in both groups were
satisfied with the program and preferred to continue the
program during chemotherapy. These findings indicate the
clinical applicability of the program; moreover, the inter-
vention does not require costly resources and is not labor
extensive.
The limitations of our study should be noted in inter-
preting outcomes of our trial and clinical application. First,
only short-term effects of the SM program on constipation
were evaluated (i.e., 4 days of the first cycle of
chemotherapy). Although a longitudinal analysis was not
performed, the duration of assessment used in our trial was
Fig. 2 Change in findings of self-evaluation of antiemetic-induced
constipation. The 2 boxes on the left indicate the score after the first
cycle of chemotherapy (C1), as adjusted by the baseline score
(C1-baseline). The mean change in the constipation assessment scale
(CAS) was significantly lower in the intervention group than in the
control group [mean, 2.0 vs. 5.0; 95 % confidence interval (-5.46 to
-0.54); **P = 0.019, t test]. The box on the right indicates the score
after the second cycle of chemotherapy (C2), as adjusted by the
baseline score (C2-baseline) in the control group (waiting-list control
C1 without intervention in the hospital; C2 with intervention via out-
patient care)
Fig. 3 Change in the constipation assessment scale (CAS) results
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appropriate for assessing the effects of 5HT3 receptor
antagonist and excluding the late effects of chemotherapy,
including docetaxel-induced diarrhea, which would con-
found the outcomes. Moreover, lifestyle and nutrition were
well controlled in the first cycle of chemotherapy, which
was administered in the hospital, compared with the second
cycle of chemotherapy, which was administered through
the ambulatory out-patient department. Second, an open-
labeled, non-blinded design was unavoidable. However,
this randomized controlled design minimized the effects of
unknown confounding factors and we taught general self-
care methods patients in both groups to minimize differ-
ences in expectancy between groups. Third, our study did
not include clinician-reported outcomes in the analysis,
such as those assessed by the CTCAE. Patient-reported
outcomes were used due to their higher concordance with
quality of life, compared to CTCAE [31]. Fourth, the mean
difference in CAS score between the intervention and
control groups was relatively small. As the CAS uses a
checklist for constipation symptoms, the overall scores
tend to be lower; for instance, the score for morphine-
induced severe constipation was 7.6/16. In general, 5 points
on the CAS is indicative of severe constipation requiring
medical intervention, compared to 0–2 points indicating
minor symptoms not requiring intervention [20, 21].
Hence, even a small difference (5 points on the CAS in the
control group vs. 2 points on the CAS in the intervention
group) would be significant in clinical situations.
A recent review reported that exercises or massage are
effective to alleviate other types of constipation, although
there was previously no evidence that a SM program could
help mitigate 5HT3 receptor antagonist-induced constipa-
tion [8, 11, 13–15]. Bidirectional brain-gut interactions
involving 5-HT pathways are important in gastrointestinal
functioning [32–35]. Although psychological well-being
may cause additional expectancy effects in patient-reported
outcomes, it is difficult to fractionate constipation and
psychological states [32–35]. According to a previous
study, increases in physical activity or SM skills may
stimulate physical functioning, such as the volume of stool,
reduce the occurrence of severe depressive symptoms, and
promote emotional well-being [32, 36, 37]. This simple,
effective, comfortable, and low-cost program for antie-
metic-induced constipation may apply to other types of
cancer patients or patients who suffer from other types of
constipation, such as opioid-induced or chronic
constipation.
In conclusion, for breast cancer patients who undergo
chemotherapy and control nausea and vomiting using
Fig. 4 Radar chart for the
components of the constipation
assessment scale, adjusted by
the baseline score, with P values
determined by the Wilcoxon
rank-sum test. The solid line
shows the score for the
intervention group and the
dotted line shows the score for
the control group
Fig. 5 Impressions and satisfaction with the self-management pro-
gram: 1 ease of use, 2 perception of whether it was effective, 3 desire
to continue with the program, 4 appropriate timing, M abdominal
massage, E abdominal exercise, P proper defecation position
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5HT3 receptor antagonists, our program offers a precise
method for managing abdominal discomfort. Future trials,
with a long-term follow-up, a wider population range, and
placebo-controlled design are needed to verify the longi-
tudinal and general effect of this SM program.
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